Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial (SoraDox)
This study is currently recruiting participants.
Verified January 2013 by Martin-Luther-Universität Halle-Wittenberg
Sponsor:
PD Dr. med. Matthias Dollinger
Information provided by (Responsible Party):
PD Dr. med. Matthias Dollinger, Martin-Luther-Universität Halle-Wittenberg
ClinicalTrials.gov Identifier:
NCT01272557
First received: January 6, 2011
Last updated: January 25, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | October 2014 |
| Estimated Primary Completion Date: | October 2013 (Final data collection date for primary outcome measure) |